At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Immuneering said that the company would test its lead product candidate Atebimetinib, in combination with Olomorasib, in a planned mid-stage clinical trial in patients with a type of non-small cell ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Indianapolis-based pharmaceutical giant Eli Lilly and Company has purchased a 323,930-square-foot industrial building in the Village of Bristol in ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...